|
05 Jan 2023 |
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
|
|
05 Jan 2023 |
Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs
|
|
05 Jan 2023 |
Checkpoint Therapeutics Submits Biologics License Application to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
|
|
05 Jan 2023 |
IntoCell Enters into Development and License Option Agreement with ADC Therapeutics
|
|
05 Jan 2023 |
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
|
|
05 Jan 2023 |
Nirsevimab US regulatory submission accepted for the prevention of RSV lower respiratory tract disease in infants and children up to age 24 months
|
|
04 Jan 2023 |
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
|
|
04 Jan 2023 |
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
|
|
04 Jan 2023 |
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
|
|
04 Jan 2023 |
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
|
|
04 Jan 2023 |
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Ca
|
|
03 Jan 2023 |
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
|
|
03 Jan 2023 |
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
|
|
03 Jan 2023 |
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
|
|
03 Jan 2023 |
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
|
|
03 Jan 2023 |
ProfoundBio Announces Initiation of First-in-Human Trial for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 Inhibitor Payload, and Receives FDA "Study May Proceed" Letter for PRO1160, a CD70-Directed ADC
|
|
02 Jan 2023 |
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
|
|
28 Dec 2022 |
Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)
|
|
28 Dec 2022 |
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
|
|
28 Dec 2022 |
TG Therapeutics Announces FDA Approval of BRIUMVI™ (ublituximab-xiiy)
|
|
23 Dec 2022 |
UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab
|
|
23 Dec 2022 |
Outlook Therapeutics® Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD
|
|
23 Dec 2022 |
Merck KGaA, Darmstadt, Germany Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
|
|
23 Dec 2022 |
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
|
|
23 Dec 2022 |
Elpiscience Announces CDE IND Clearance of ES014, a First in Class Anti-CD39xTGF-β Bispecific Antibody for Patients with Advanced Solid Tumors
|
